Submissions

CHPA supports FDA’s continued efforts to support medical device innovation by facilitating to the use of PCCPs for efficient Agency review of medical device modifications. When finalizing the Draft Guidance, CHPA strongly encourages FDA to provide further clarity regarding the content and process for PCCPs on several points.

CHPA supports the Agency’s directive to increase enrollment of participants from historically underrepresented populations in clinical trials to improve the strength and generalizability of the evidence to demonstrate safety and/or effectiveness of FDA-regulated medical products, but requests clarification on several points.

CHPA submits these comments on FDA’s Annual Reportable Labeling Changes for New Drug Applications and Abbreviated New Drug Applications for Nonprescription Drug Products; Draft Guidance for Industry issued on March 13, 2024.

CHPA acknowledges and supports FDA’s endeavors to modernize inspection and compliance strategies through the integration of Remote Regulatory Assessments (RRAs). This approach, when harmonized with other regulatory oversight tools, has the potential to contribute significantly to a more efficient, risk-based, and focused inspection system.

CHPA looks forward to working closely with FDA and other key stakeholders throughout the OMUFA reauthorization process as we work together to ensure the continued success of FDA’s OTC monograph program.

Pursuant to 16 C.F.R. § 1.31, through this petition, Petitioners respectfully request that FTC withdraw the notice of penalty offenses that were sent to nearly 700 companies.

CHPA strongly urges the Food and Drug Administration to deny the petition to repeal 21 CFR 73.575, which permits the use of TiO2 in food and dietary supplements. Based on extensive scientific research and regulatory evaluations, TiO2 is deemed safe for use as a food additive when consumed within established regulatory limits.